RU2004112546A - Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина - Google Patents
Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина Download PDFInfo
- Publication number
- RU2004112546A RU2004112546A RU2004112546/15A RU2004112546A RU2004112546A RU 2004112546 A RU2004112546 A RU 2004112546A RU 2004112546/15 A RU2004112546/15 A RU 2004112546/15A RU 2004112546 A RU2004112546 A RU 2004112546A RU 2004112546 A RU2004112546 A RU 2004112546A
- Authority
- RU
- Russia
- Prior art keywords
- activity against
- disorders
- use according
- disorder
- composition
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims 21
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title claims 15
- 230000036961 partial effect Effects 0.000 title claims 15
- 230000001270 agonistic effect Effects 0.000 title claims 12
- 102000015554 Dopamine receptor Human genes 0.000 title claims 10
- 108050004812 Dopamine receptor Proteins 0.000 title claims 10
- 239000000203 mixture Substances 0.000 claims 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 229960002748 norepinephrine Drugs 0.000 claims 14
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 229940076279 serotonin Drugs 0.000 claims 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 4
- 229960003638 dopamine Drugs 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 230000006399 behavior Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 238000002474 experimental method Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000001690 micro-dialysis Methods 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000027559 Appetite disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 206010013496 Disturbance in attention Diseases 0.000 claims 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000001613 Gambling Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 208000036353 Rett disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 2
- 208000007656 osteochondritis dissecans Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001730 monoaminergic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000697 serotonin reuptake Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020076344 EP1336406A1 (en) | 2002-02-14 | 2002-02-14 | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| EP02076344.7 | 2002-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004112546A true RU2004112546A (ru) | 2005-03-27 |
Family
ID=27619173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004112546/15A RU2004112546A (ru) | 2002-02-14 | 2003-02-11 | Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050038015A1 (enExample) |
| EP (2) | EP1336406A1 (enExample) |
| JP (1) | JP2005517036A (enExample) |
| KR (1) | KR20040081779A (enExample) |
| CN (1) | CN1592614A (enExample) |
| AU (1) | AU2003208714A1 (enExample) |
| BR (1) | BR0306147A (enExample) |
| CA (1) | CA2462688A1 (enExample) |
| HR (1) | HRP20040276A2 (enExample) |
| IL (1) | IL160942A0 (enExample) |
| MX (1) | MXPA04004745A (enExample) |
| NO (1) | NO20043833L (enExample) |
| PL (1) | PL370632A1 (enExample) |
| RU (1) | RU2004112546A (enExample) |
| WO (1) | WO2003068207A2 (enExample) |
| ZA (1) | ZA200404740B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287018B6 (sk) | 1999-08-23 | 2009-09-07 | Solvay Pharmaceuticals B. V. | Deriváty fenylpiperazínov, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AR032712A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
| AR032711A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene |
| WO2003007956A1 (en) * | 2001-07-20 | 2003-01-30 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| WO2004060374A1 (en) | 2002-12-27 | 2004-07-22 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| EP1595542A1 (en) * | 2004-03-26 | 2005-11-16 | Solvay Pharmaceuticals B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| WO2007019880A1 (en) * | 2005-08-18 | 2007-02-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome |
| WO2007065713A2 (en) * | 2005-12-08 | 2007-06-14 | Axxonis Pharma Gmbh | Use of 8-alpha-ergolines for the treatment of traumatic brain disorders |
| CA2677219A1 (en) | 2007-02-01 | 2009-01-29 | Alan I. Green | Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade |
| EP2182952A4 (en) * | 2007-07-23 | 2010-09-08 | Synosia Therapeutics | TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
| TW200936130A (en) * | 2008-02-26 | 2009-09-01 | Lundbeck & Co As H | Uses of indane compounds |
| WO2011082266A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| EP3231446A1 (en) * | 2010-04-19 | 2017-10-18 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| CN111134894B (zh) * | 2020-01-17 | 2022-02-22 | 上海长海医院 | 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71590C2 (en) * | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| SK287018B6 (sk) * | 1999-08-23 | 2009-09-07 | Solvay Pharmaceuticals B. V. | Deriváty fenylpiperazínov, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie |
-
2002
- 2002-02-14 EP EP20020076344 patent/EP1336406A1/en not_active Withdrawn
-
2003
- 2003-02-11 MX MXPA04004745A patent/MXPA04004745A/es unknown
- 2003-02-11 KR KR10-2004-7012355A patent/KR20040081779A/ko not_active Ceased
- 2003-02-11 RU RU2004112546/15A patent/RU2004112546A/ru not_active Application Discontinuation
- 2003-02-11 CA CA002462688A patent/CA2462688A1/en not_active Abandoned
- 2003-02-11 HR HR20040276A patent/HRP20040276A2/hr not_active Application Discontinuation
- 2003-02-11 AU AU2003208714A patent/AU2003208714A1/en not_active Abandoned
- 2003-02-11 JP JP2003567389A patent/JP2005517036A/ja not_active Withdrawn
- 2003-02-11 EP EP03706621A patent/EP1476148A2/en not_active Withdrawn
- 2003-02-11 PL PL03370632A patent/PL370632A1/xx not_active Application Discontinuation
- 2003-02-11 IL IL16094203A patent/IL160942A0/xx unknown
- 2003-02-11 WO PCT/EP2003/050015 patent/WO2003068207A2/en not_active Ceased
- 2003-02-11 CN CNA038015544A patent/CN1592614A/zh active Pending
- 2003-02-11 US US10/490,365 patent/US20050038015A1/en not_active Abandoned
- 2003-02-11 BR BR0306147-7A patent/BR0306147A/pt not_active IP Right Cessation
-
2004
- 2004-06-15 ZA ZA200404740A patent/ZA200404740B/en unknown
- 2004-09-13 NO NO20043833A patent/NO20043833L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1336406A1 (en) | 2003-08-20 |
| IL160942A0 (en) | 2004-08-31 |
| JP2005517036A (ja) | 2005-06-09 |
| KR20040081779A (ko) | 2004-09-22 |
| US20050038015A1 (en) | 2005-02-17 |
| CA2462688A1 (en) | 2003-08-21 |
| WO2003068207A3 (en) | 2003-12-18 |
| CN1592614A (zh) | 2005-03-09 |
| NO20043833L (no) | 2004-09-13 |
| AU2003208714A1 (en) | 2003-09-04 |
| HRP20040276A2 (en) | 2005-04-30 |
| MXPA04004745A (es) | 2004-08-02 |
| PL370632A1 (en) | 2005-05-30 |
| BR0306147A (pt) | 2004-10-19 |
| WO2003068207A2 (en) | 2003-08-21 |
| ZA200404740B (en) | 2005-08-23 |
| EP1476148A2 (en) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004112546A (ru) | Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина | |
| JP2005517036A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| CO5190662A1 (es) | Inhibidores altamente selectivos de la recaptacion de la norepinefrina y metodos de uso de los mismos | |
| RU2007139541A (ru) | Производные хромана и хромена и их применение | |
| RU2007139543A (ru) | Производные бензодиоксана и бензодиоксолана и их применение | |
| RU2012149042A (ru) | Конъюгат (варианты), способ лечения заболеваний нервной системы (варианты), способ визуализации клетки, диагностическое средство, амидные соединения (варианты), способ получения конъюгата и способы получения амидных соединений | |
| RU2011119990A (ru) | Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| EP1749818A3 (en) | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | |
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| RU2008138532A (ru) | Стандарты варениклина и контроль примесей | |
| KR960007568A (ko) | 트리사이클릭 피라졸 유도체 | |
| JP2009527462A5 (enExample) | ||
| JP2005524713A5 (enExample) | ||
| UY26924A1 (es) | Derivados de fenoxibencilamina como ssri | |
| WO2010121225A3 (en) | Method of treating disorders associated with protein kinase ck2 activity | |
| ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
| ATE425752T1 (de) | Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen | |
| DE69935331D1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| JP2006503062A5 (enExample) | ||
| WO2006058016A3 (en) | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| JPWO2020132474A5 (enExample) | ||
| SE9904750D0 (sv) | New formulation, use and method | |
| RU2006114051A (ru) | Производные гекса- и октагидропиридо [1,2-а]пиразина сnk1-антагонической активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060912 |